Natasha Persaud

In a large case series, stage IV disease at diagnosis and 3 or more metastatic sites were both associated with worse prognosis.

In a small study, 1 in 3 prostate cancer patients who underwent salvage robotic-assisted radical prostatectomy following partial ablation with high-intensity focused ultrasound required adjuvant radiation or androgen deprivation therapy within 12 months.

Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found.

Confirmatory biopsy with MRI guidance provides a more accurate risk assessment than a conventional transrectal ultrasound confirmatory biopsy, according to researchers.

In a real-world study, cytoreductive nephrectomy (CN) prior to treatment with tyrosine kinase inhibitors did not improve survival for CN recipients overall, but did improve cancer-specific and progression-free survival in certain subgroups.

Template-based lymph node dissection in patients with upper tract urothelial carcinoma could facilitate better local disease control by eliminating micrometastasis, according to investigators.

In a study involving stage 3 RCC patients, those with positive lymph nodes had markedly inferior 5-year survival compared with those with lymph-node negative disease and 5-year survival similar to those with stage 4 RCC.

In the phase 3 HERO trial, more relugolix than leuprolide recipients achieved sustained testosterone suppression over 48 weeks: 96.7% vs 88.8%, respectively.

In the PROSPER study, median overall survival was significantly longer among enzalutamide-treated patients compared with placebo recipients (67.0 vs 56.3 months).

A study found no survival differences between high-grade UTUC patients who at the time of radical nephroureterectomy achieved low-grade disease following neoadjuvant chemotherapy and those who had inherently low-stage disease and did not receive chemotherapy.